Trial Profile
Trial of Afatinib (BIBW 2992) in Suspected or Confirmed Mutant EGFR Lung Cancer Patients Unfit for Chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms TIMELY
- 11 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Sep 2018 Results presented at the 19th World Conference on Lung Cancer
- 09 May 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.